| 3142 |
10.1016/j.annonc.2020.04.010 |
Updated Efficacy Results From The Javelin Renal 101
Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib In Patients
With Advanced Renal Cell Carcinoma |
Choueiri, T.K.; Motzer, R.J.; Rini, B.I.; Haanen, J.;
Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Gravis-Mescam, G.;
Uemura, M.; Lee, J.L.; Grimm, M.-O.; Gurney, H.; Schmidinger, M.;
Larkin, J.; Atkins, M.B.; Pal, S.K.; Wang, J.; Mariani, M.;
Krishnaswami, S.; Cislo, P.; Chudnovsky, A.; Fowst, C.; Huang, B.; Di
Pietro, A.; Albiges, L. |
Annals Of Oncology |
2020 |
| 3147 |
10.1016/j.annonc.2020.08.2257 |
696O_Pr Nivolumab + Cabozantinib Vs Sunitinib In
First-Line Treatment For Advanced Renal Cell Carcinoma: First Results
From The Randomized Phase Iii Checkmate 9Er Trial |
Choueiri, T.K.; Powles, T.; Burotto, M.; Bourlon, M.T.;
Zurawski, B.; Oyervides Juarez, V.M.; Hsieh, J.J.; Basso, U.; Shah,
A.Y.; Suarez, C.; Hamzaj, A.; Barrios, C.H.; Richardet, M.; Pook, D.;
Tomita, Y.; Escudier, B.; Zhang, J.; Simsek, B.; Apolo, A.B.; Motzer,
R.J. |
Annals Of Oncology |
2020 |
| 5449 |
10.1016/j.ejca.2018.11.031 |
Second-Line Targeted Therapies After
Nivolumab-Ipilimumab Failure In Metastatic Renal Cell Carcinoma |
Auvray, Marie, 0000-0002-1258-861X; Auclin, Edouard;
Barthelemy, Philippe; Bono, Petri; Kellokumpu-Lehtinen, Pirkko;
Gross-Goupil, Marine; De Velasco, Guillermo, 0000-0002-8075-0666;
Powles, Thomas; Mouillet, Guillaume, 0000-0002-2288-7461; Vano,
Yann-Alexandre; Gravis, Gwenaelle; Mourey, Loic; Priou, Franck; Rolland,
Frederic; Escudier, Bernard; Albiges, Laurence |
European Journal Of Cancer |
2019 |
| 5994 |
10.1016/j.eururo.2019.05.022 |
Updated European Association Of Urology Guidelines On
Renal Cell Carcinoma: Immune Checkpoint Inhibition Is The New Backbone
In First-Line Treatment Of Metastatic Clear-Cell Renal Cell
Carcinoma |
Albiges, Laurence; Powles, Tom; Staehler, Michael;
Bensalah, Karim; Giles, Rachel H.; Hora, Milan; Kuczyk, Markus A.; Lam,
Thomas B.; Ljungberg, Borje; Marconi, Lorenzo; Merseburger, Axel S.;
Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed;
Fernandez-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana;
Bex, Axel |
European Urology |
2019 |
| 10119 |
10.1016/s0140-6736(19)30723-8 |
Atezolizumab Plus Bevacizumab Versus Sunitinib In
Patients With Previously Untreated Metastatic Renal Cell Carcinoma
(Immotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled
Trial |
Rini, Brian I; Powles, Thomas; Atkins, Michael B;
Escudier, Bernard; Mcdermott, David F; Suarez, Cristina; Bracarda,
Sergio; Stadler, Walter M; Donskov, Frede; Lee, Jae Lyun; Hawkins,
Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura,
Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar,
Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K; Parnis,
Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis,
Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green,
Marjorie C; Motzer, Robert J |
The Lancet |
2019 |
| 10266 |
10.1016/s1470-2045(18)30648-x |
Genomically Annotated Risk Model For Advanced
Renal-Cell Carcinoma: A Retrospective Cohort Study |
Voss, Martin H; Reising, Albert; Cheng, Yuan; Patel,
Parul; Marker, Mahtab; Kuo, Fengshen; Chan, Timothy A; Choueiri, Toni K;
Hsieh, James J; Hakimi, A Ari; Motzer, Robert J |
The Lancet Oncology |
2018 |
| 10272 |
10.1016/s1470-2045(18)30778-2 |
Patient-Reported Outcomes Of Patients With Advanced
Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Versus
Sunitinib (Checkmate 214): A Randomised, Phase 3 Trial |
Cella, David; Grunwald, Viktor; Escudier, Bernard;
Hammers, Hans J; George, Saby; Nathan, Paul; Grimm, Marc-Oliver; Rini,
Brian I; Doan, Justin; Ivanescu, Cristina; Paty, Jean; Mekan, Sabeen;
Motzer, Robert J |
The Lancet Oncology |
2019 |
| 10299 |
10.1016/s1470-2045(19)30413-9 |
Nivolumab Plus Ipilimumab Versus Sunitinib In
First-Line Treatment For Advanced Renal Cell Carcinoma: Extended
Follow-Up Of Efficacy And Safety Results From A Randomised, Controlled,
Phase 3 Trial |
Motzer, Robert J; Rini, Brian I; Mcdermott, David F;
Aren Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman,
Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta,
Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott
S; Barthelemy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R;
Oosting, Sjoukje F; Redman, Bruce; Melichar, Bohuslav; Powles, Thomas;
Nathan, Paul; Oudard, Stephane; Pook, David; Choueiri, Toni K; Donskov,
Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y C;
Kollmannsberger, Christian K; Harrison, Michael R; Tomita, Yoshihiko;
Duran, Ignacio; Grunwald, Viktor; Mchenry, M Brent; Mekan, Sabeen;
Tannir, Nizar M |
The Lancet Oncology |
2019 |
| 10313 |
10.1016/s1470-2045(19)30735-1 |
Tivozanib Versus Sorafenib In Patients With Advanced
Renal Cell Carcinoma (Tivo-3): A Phase 3, Multicentre, Randomised,
Controlled, Open-Label Study |
Rini, Brian I; Pal, Sumanta K; Escudier, Bernard J;
Atkins, Michael B; Hutson, Thomas E; Porta, Camillo; Verzoni, Elena;
Needle, Michael N; Mcdermott, David F |
The Lancet Oncology |
2020 |
| 10341 |
10.1016/s1470-2045(20)30436-8 |
Pembrolizumab Plus Axitinib Versus Sunitinib
Monotherapy As First-Line Treatment Of Advanced Renal Cell Carcinoma
(Keynote-426): Extended Follow-Up From A Randomised, Open-Label, Phase 3
Trial |
Powles, Thomas; Plimack, Elizabeth R; Soulieres, Denis;
Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot,
Frederic; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J;
Borchiellini, Delphine; Mcdermott, Raymond S; Bedke, Jens; Tamada,
Satoshi; Yin, Lina; Chen, Mei; Molife, L Rhoda; Atkins, Michael B; Rini,
Brian I |
The Lancet Oncology |
2020 |
| 14642 |
10.1038/s41591-018-0053-3 |
Clinical Activity And Molecular Correlates Of Response
To Atezolizumab Alone Or In Combination With Bevacizumab Versus
Sunitinib In Renal Cell Carcinoma |
Mcdermott, David F.; Huseni, Mahrukh A.; Atkins,
Michael B.; Motzer, Robert J.; Rini, Brian I.; Escudier, Bernard; Fong,
Lawrence; Joseph, Richard W.; Pal, Sumanta K.; Reeves, James A.; Sznol,
Mario; Hainsworth, John; Rathmell, W. Kimryn; Stadler, Walter M.;
Hutson, Thomas; Gore, Martin E.; Ravaud, Alain; Bracarda, Sergio;
Suarez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni
K.; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth;
Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S.; Hegde, Priti S.; Schiff,
Christina; Fine, Gregg D.; Powles, Thomas |
Nature Medicine |
2018 |
| 16031 |
10.1056/nejmoa1712126 |
Nivolumab Plus Ipilimumab Versus Sunitinib In Advanced
Renal-Cell Carcinoma |
Motzer, Robert J.; Tannir, Nizar M.; Mcdermott, David
F.; Aren Frontera, Osvaldo; Melichar, Bohuslav; Choueiri, Toni K.;
Plimack, Elizabeth R.; Barthelemy, Philippe; Porta, Camillo; George,
Saby; Powles, Thomas; Donskov, Frede; Neiman, Victoria; Kollmannsberger,
Christian K.; Salman, Pamela; Gurney, Howard; Hawkins, Robert; Ravaud,
Alain; Grimm, Marc-Oliver; Bracarda, Sergio; Barrios, Carlos H.; Tomita,
Yoshihiko; Castellano, Daniel; Rini, Brian I.; Chen, Allen C.; Mekan,
Sabeen; Mchenry, M. Brent; Wind-Rotolo, Megan; Doan, Justin; Sharma,
Padmanee; Hammers, Hans J.; Escudier, Bernard |
New England Journal Of Medicine |
2018 |
| 16096 |
10.1056/nejmoa1816047 |
Avelumab Plus Axitinib Versus Sunitinib For Advanced
Renal-Cell Carcinoma |
Motzer, Robert J.; Penkov, Konstantin; Haanen, John;
Rini, Brian; Albiges, Laurence; Campbell, Matthew T.; Venugopal, Balaji;
Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae
L.; Vasiliev, Aleksandr; Miller, Wilson H.; Gurney, Howard; Schmidinger,
Manuela; Larkin, James; Atkins, Michael B.; Bedke, Jens; Alekseev,
Boris; Wang, Jing; Mariani, Mariangela; Robbins, Paul B.; Chudnovsky,
Aleksander; Fowst, Camilla; Hariharan, Subramanian; Huang, Bo; Di
Pietro, Alessandra; Choueiri, Toni K. |
New England Journal Of Medicine |
2019 |
| 16097 |
10.1056/nejmoa1816714 |
Pembrolizumab Plus Axitinib Versus Sunitinib For
Advanced Renal-Cell Carcinoma |
Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor;
Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic;
Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko,
Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Azevedo, Sergio J.;
Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; Mcdermott,
Raymond S.; Bedke, Jens; Tartas, Sophie; Chang, Yen-Hwa; Tamada,
Satoshi; Shou, Qiong; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.;
Powles, Thomas |
New England Journal Of Medicine |
2019 |
| 16204 |
10.1056/nejmoa2026982 |
Nivolumab Plus Cabozantinib Versus Sunitinib For
Advanced Renal-Cell Carcinoma |
Choueiri, Toni K.; Powles, Thomas; Burotto, Mauricio;
Escudier, Bernard; Bourlon, Maria T.; Zurawski, Bogdan; Oyervides
Juarez, Victor M.; Hsieh, James J.; Basso, Umberto; Shah, Amishi Y.;
Suarez, Cristina; Hamzaj, Alketa; Goh, Jeffrey C.; Barrios, Carlos;
Richardet, Martin; Porta, Camillo; Kowalyszyn, Ruben; Feregrino, Juan
P.; <U+017B>o<U+0142>nierek, Jakub; Pook, David; Kessler,
Elizabeth R.; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang,
Joshua; Maurer, Matthew A.; Simsek, Burcin; Ejzykowicz, Flavia; Schwab,
Gisela M.; Apolo, Andrea B.; Motzer, Robert J. |
New England Journal Of Medicine |
2021 |
| 16228 |
10.1056/nejmoa2035716 |
Lenvatinib Plus Pembrolizumab Or Everolimus For
Advanced Renal Cell Carcinoma |
Motzer, Robert; Alekseev, Boris; Rha, Sun-Young; Porta,
Camillo; Eto, Masatoshi; Powles, Thomas; Grunwald, Viktor; Hutson,
Thomas E.; Kopyltsov, Evgeny; Mendez-Vidal, Maria J.; Kozlov, Vadim;
Alyasova, Anna; Hong, Sung-Hoo; Kapoor, Anil; Alonso Gordoa, Teresa;
Merchan, Jaime R.; Winquist, Eric; Maroto, Pablo; Goh, Jeffrey C.; Kim,
Miso; Gurney, Howard; Patel, Vijay; Peer, Avivit; Procopio, Giuseppe;
Takagi, Toshio; Melichar, Bohuslav; Rolland, Frederic; De Giorgi, Ugo,
0000-0001-7520-2908; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela;
Dutcus, Corina E.; Smith, Alan D.; Dutta, Lea; Mody, Kalgi; Perini,
Rodolfo F.; Xing, Dongyuan; Choueiri, Toni K. |
New England Journal Of Medicine |
2021 |
| 16975 |
10.1093/annonc/mdz056 |
Renal Cell Carcinoma: Esmo Clinical Practice Guidelines
For Diagnosis, Treatment And Follow-Up |
Escudier, B.; Porta, C.; Schmidinger, M.;
Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grunwald, V.; Gillessen, S.;
Horwich, A. |
Annals Of Oncology |
2019 |
| 19231 |
10.1136/esmoopen-2020-001079 |
Nivolumab Plus Ipilimumab Versus Sunitinib For
First-Line Treatment Of Advanced Renal Cell Carcinoma: Extended 4-Year
Follow-Up Of The Phase Iii Checkmate 214 Trial |
Albiges, Laurence, 0000-0002-5734-3480; Tannir, Nizar
M.; Burotto, Mauricio; Mcdermott, David; Plimack, Elizabeth R.;
Barthelemy, Philippe; Porta, Camillo, 0000-0003-2412-1563; Powles,
Thomas; Donskov, Frede; George, Saby; Kollmannsberger, Christian K.;
Gurney, Howard; Grimm, Marc-Oliver; Tomita, Yoshihiko; Castellano,
Daniel; Rini, Brian I.; Choueiri, Toni K.; Saggi, Shruti Shally;
Mchenry, M. Brent; Motzer, Robert J. |
Esmo Open |
2020 |
| 19274 |
10.1136/jitc-2020-000891 |
Survival Outcomes And Independent Response Assessment
With Nivolumab Plus Ipilimumab Versus Sunitinib In Patients With
Advanced Renal Cell Carcinoma: 42-Month Follow-Up Of A Randomized Phase
3 Clinical Trial |
Motzer, Robert J, 0000-0001-6925-2327; Escudier,
Bernard; Mcdermott, David F; Aren Frontera, Osvaldo; Melichar, Bohuslav;
Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthelemy,
Philippe; Hammers, Hans J; George, Saby; Grunwald, Viktor; Porta,
Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K,
0000-0002-9201-3217; Rini, Brian I; Salman, Pamela; Kollmannsberger,
Christian K; Tykodi, Scott S; Grimm, Marc-Oliver; Gurney, Howard;
Leibowitz-Amit, Raya; Geertsen, Poul F; Amin, Asim; Tomita, Yoshihiko;
Mchenry, M Brent; Saggi, Shruti Shally; Tannir, Nizar M |
Journal For Immunotherapy Of Cancer |
2020 |
| 19535 |
10.1158/2159-8290.cd-18-0957 |
Transcriptomic Profiling Of The Tumor Microenvironment
Reveals Distinct Subgroups Of Clear Cell Renal Cell Cancer: Data From A
Randomized Phase Iii Trial |
Hakimi, A. Ari; Voss, Martin H., 0000-0003-0551-5807;
Kuo, Fengshen, 0000-0003-1797-2896; Sanchez, Alejandro; Liu, Ming;
Nixon, Briana G.; Vuong, Lynda; Ostrovnaya, Irina; Chen, Ying-Bei,
0000-0001-5207-3648; Reuter, Victor; Riaz, Nadeem; Cheng, Yuan; Patel,
Parul; Marker, Mahtab; Reising, Albert; Li, Ming O.; Chan, Timothy A.;
Motzer, Robert J., 0000-0001-6925-2327 |
Cancer Discovery |
2019 |
| 20187 |
10.1186/s40425-018-0420-0 |
Safety And Efficacy Of Nivolumab In Combination With
Sunitinib Or Pazopanib In Advanced Or Metastatic Renal Cell Carcinoma:
The Checkmate 016 Study |
Amin, Asim; Plimack, Elizabeth R; Ernstoff, Marc S;
Lewis, Lionel D; Bauer, Todd M; Mcdermott, David F; Carducci, Michael;
Kollmannsberger, Christian; Rini, Brian I; Heng, Daniel Y C; Knox,
Jennifer; Voss, Martin H; Spratlin, Jennifer; Berghorn, Elmer; Yang,
Lingfeng; Hammers, Hans J |
Journal For Immunotherapy Of Cancer |
2018 |
| 20325 |
10.1200/jco.2019.37.15_suppl.101 |
Biomarker Analyses From Javelin Renal 101: Avelumab +
Axitinib (A+Ax) Versus Sunitinib (S) In Advanced Renal Cell Carcinoma
(Arcc). |
Choueiri, Toni K.; Albiges, Laurence; Haanen, John B.
A. G.; Larkin, James M.G.; Uemura, Motohide; Pal, Sumanta K.; Gravis,
Gwenaelle; Campbell, Matthew T; Penkov, Konstantin; Lee, Jae-Lyun;
Ching, Keith A.; Mu, Xinmeng Jasmine; Wang, Xiao; Zhang, Weidong; Wang,
Jing; Chudnovsky, Aleksander; Di Pietro, Alessandra; Robbins, Paul B.;
Motzer, Robert J. |
Journal Of Clinical Oncology |
2019 |
| 20331 |
10.1200/jco.2019.37.15_suppl.4500 |
Pembrolizumab (Pembro) Plus Axitinib (Axi) Versus
Sunitinib As First-Line Therapy For Metastatic Renal Cell Carcinoma
(Mrcc): Outcomes In The Combined Imdc Intermediate/Poor Risk And
Sarcomatoid Subgroups Of The Phase 3 Keynote-426 Study. |
Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor;
Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic;
Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio
Jobim; Borchiellini, Delphine; Mcdermott, Raymond S.; Bedke, Jens;
Tamada, Satoshi; Wan, Shuyan; Perini, Rodolfo F.; Chen, Mei; Atkins,
Michael B.; Powles, Thomas |
Journal Of Clinical Oncology |
2019 |